Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IGBA Makes Access Pact With WHO

Promotes The Use Of Generics And Biosimilars

Executive Summary

The WHO has taken an “important first step” towards increased collaboration with the generics and biosimilars industries through an agreement with the IGBA to promote access to medicines, including working towards a reduced trial burden for biosimilars and speeding up registration for both generics and biosimilars.

You may also be interested in...

IGBA Builds On Partnership With WHO

In the first in a series of exclusive interviews, IGBA chair Hanan Sboul talks about the international off-patent industry association’s collaboration with the WHO and how it is expected to develop in future.

Sboul Is Appointed IGBA Chair

Hanan Sboul, secretary general of the Jordanian Association of Pharmaceutical Manufacturers, has been named as chair of the International Generic and Biosimilar medicines Association. She takes over from Jim Keon, president of the Canadian Generic Pharmaceutical Association.

WHO Committee Wants Biosimilars Added To Pre-Qualification

As biosimilars are added to the WHO’s list of essential drugs, an expert committee wants the global body to expand its pre-qualification program to cover more biosimilars.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts